Acta Pharmaceuticals Raises $24M Seed Funding

Acta Pharmaceuticals, a Boston-based biotechnology company, secured $24 million in seed financing to advance its Alzheimer's disease drug development pipeline. Founded in 2022, the firm supports lead candidate GSM-779690T and combination therapies derived from decades of research. The capital funds preclinical studies planned for October 2026 involving healthy adult volunteers to assess safety and tolerability before any human trials begin.